Oncology
5,176 studies502 in 7 days2,477 in 30 days
Filters
Latest
5,176 studies
- 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
- 1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer
- 1190 Spatial and phenotypic characterization of tertiary lymphoid structures and immune organization in cutaneous squamous cell carcinoma using multiplex immunofluorescence
- 1175 Combining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancer
- 1191 Neoadjuvant phase 1b results: dose escalation of intratumoral PH-762 for cutaneous SCC, melanoma, or Merkel cell ( NCT06014086)
- Artificial intelligence-driven precision immunogenetics for cancer stem cell-targeted CAR immunotherapy
- 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
- 1098 A 3D tumor-stroma-immune co-culture platform for bispecific antibody screening in pancreatic ductal adenocarcinoma
- 330 Multi-omic analysis of TIL therapy in advanced checkpoint-refractory melanoma
- 531 Phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma
- 442 Characterization of transcriptomic programs and rare somatic mutations affecting survival and immune checkpoint inhibitor (ICI) response in clear-cell renal cell carcinoma (ccRCC)
- EGF and EREG regulate early oncoprotein-mediated tissue transformation in intestinal organoids.
- Pulmonary Large-Cell Neuroendocrine Carcinoma: Molecular Heterogeneity, Current Treatment and the Emerging Precision-Oncology Paradigm
- Immunotherapies and Chemo-Sparing Approaches: A New Era for Diffuse Large B-Cell Lymphoma in Older Patients
- Motor Deficits After Insular Glioma Surgery: Association with Postoperative Ischemia and Intraoperative Neuromonitoring
- Metabolomics in Thoracic Oncology from Biomarker Discovery to Therapeutic Targeting: A Narrative Review
- Predictors of Benefit from Immune Checkpoint Inhibitors in Urothelial Carcinoma of the Bladder: The Limits of PD-L1 and the Rise of Circulating Tumor DNA-Guided Adjuvant Therapy
- Early-Onset Breast, Cervical, Colorectal and Stomach Cancer Across the States of India, 1990–2023: Divergent Trends and a Mismatch Between Burden Rate and Caseload
- Excess Cardiovascular Burden Among Young Patients with Cancer: A Systematic Review and Meta-Analysis
- 1012 Rational design of selective IL-2-based activators for CAR T cells Using AlphaFold3 and physics-informed machine learning
- 897 Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile
- 577 Biopsy-associated tumor regression in late relapsed DLBCL after tandem CD20-CD19 CAR-T cell therapy
- 235 Preclinical evaluation and clinical scale-up of virus-free CRISPR GD2 CAR T cells
- 698 Interferon-γ-producing exhausted T cells are critical for host memory response to melanoma
- 453 Longitudinal spatial proteomic analysis of successful immune checkpoint therapy